Mirikizumab is safe and effective in patients with moderate-to-severe Crohn’s disease
1. The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus placebo. 2. Clinical remission ...
1. The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus placebo. 2. Clinical remission ...
1. In this randomized controlled trial, patients with ulcerative colitis taking mirikizumab had higher rates of clinical remission compared to ...
Click here to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
Over the past 30 years, the transition from print to digital media has contributed to an exponential increase in medical literature. In response, 2 Minute Medicine presents 160+ authoritative, physician-written summaries of the most cited landmark trials in medicine.